HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Winkelman, J. Articles by McAfee, J. Search for Related Content PubMed PubMed Citation Articles by Winkelman, J. Articles by McAfee, J.

The Metabolism and Excretion of Co⁵⁷ Tetraphenylporphinesulfonate in Cancer Patients¹

ABSTRACT

Co⁵⁷ tetraphenylporphinesulfonate was administered to patients with malignant tumors. Its effective and biologic half life, pattern of excretion in urine and stool, and in vivo dissociation was determined. Forty-six patients with cerebral and visceral tumors and myocardial infarctions were studied by scintillation scanning. Cerebral tumors were successfully demonstrated. Tumors in other locations, however, were not delineated. It was found that approximately 40% of the Co⁵⁷ was dissociated. The failure of the radioisotope to localize in the tumors to the same extent as TPPS is explained at least partly by this dissociation.

FOOTNOTES

¹ This investigation was supported in part by Grant #IN-14E from the American Cancer Society, Inc., and Public Health Service Training Fellowing #2G-127C6.

² From the New York University School of Medicine, Department of Pathology and Radiology, New York, N.Y.

³ From the New York University School of Medicine, Department of Pathology and Radiology, New York, N.Y.

⁴ Johns Hopkins Hospital, Diagnostic Radioisotope Laboratory, Baltimore, Maryland.